

参 考 文 献

1. Zuckerman AJ: Nature, 287: 483, 1980.
2. Zuckerman AJ: J Infect Dis, 143: 301, 1981.
3. Szmuness W et al: In Vyas GN et al [ed], Viral Hepatitis, p 297, Franklin Institute Press, Philadelphia, 1978.
4. Szmuness W et al: J Med Virol, 4: 327, 1979.
5. Krugman S et al: Infectious Diseases of Children, 7th ed, p90, The C.V. Mosby Company, 1980.
6. Krugman S et al: J Infect Dis, 122: 432, 1970.
7. Soulier JP et al: Amer J Dis Child, 123: 429, 1972.
8. Purcell RH et al: Amer J Med Sci, 270: 395, 1975.
9. Buynak EB et al: Proc Soc Exp Biol Med, 151: 694, 1976.
10. Maupas P et al: Lancet, i: 1367, 1976.
11. Reesink HW et al: 17th Congress of the German Society of Blood Transfusion and Immunohematology, p 119, Frankfurt, 1976.
12. Hilleman MR et al. In Vyas GN et al [ed], Viral Hepatitis, p525, Franklin Institute Press, Philadelphia, 1978.
13. Purcell RH et al: In Vyas GN et al [ed], Viral Hepatitis, p491, Franklin Institute Press, Philadelphia, 1978.
14. Maupas, P et al: In Vyas GN et al [ed], Viral Hepatitis, p539, Franklin Institute Press, Philadelphia, 1978.
15. Hollinger FB et al: In Vyas GN et al [ed], Viral Hepatitis, p557, Franklin Institute Press, Philadelphia, 1978.
16. Reesink HW et al: In Vyas GN et al [ed], Viral Hepatitis, p714, Franklin Institute Press, Philadelphia, 1978.
17. Gerety RJ et al: J Infect Dis, 140: 642, 1979.
18. Tao CM et al: Chin Med J [Engl], 4: 101, 1978.
19. Prince AM et al: In Vyas NG et al [ed], Viral Hepatitis, p507, Franklin Institute Press, Philadelphia, 1978.
20. Crosnier J et al: Lancet, i: 455, 1981.
21. Skelley J et al: J Gen Virol, 44: 679, 1979.
22. World Health Organization: Proposed Requirement for Hepatitis B Vaccine, Biological Substance, No 31-79, p1239, 1979.
23. Summers J et al: Proc Natl Acad Sci USA, 75: 4533, 1978.
24. Marion PL et al: Proc Natl Acad Sci USA, 77: 2941, 1980.
25. Mason WS et al: J Virol, 36: 829, 1980.
26. Hirshman SZ et al: Proc Natl Acad Sci USA, 77: 5507, 1980.
27. Price P et al: J Med Virol, 6: 139, 1980.
28. McAuliffe VJ et al: Reviews of Infect Dis, 2: 470, 1980.
29. Alexander J et al: S Afr J Med Sci, 41: 89, 1976.
30. Aden P et al: Nature, 282: 615, 1979.
31. Marion PL et al: J Virol, 33: 795, 1980.
32. Trepco C et al: Lancet, i: 488, 1979.
33. Maupas p et al: Intervirology, 10: 196, 1978.
34. Barin F et al: Prog Med Virol, 27: 148, 1981.
35. Maupas P et al: Lancet, i: 289, 1981.
36. Doniach D et al: Lancet, i: 721, 1979.
37. Szmuness W et al: N Engl J Med, 303: 833, 1980.
38. Szmuness W et al: Lancet, i: 575, 1981.
39. Stevens CE et al: Lancet, ii: 1211, 1980.
40. Beasley RP et al: In Vyas GN et al [ed], Viral Hepatitis, p333, Franklin Institute Press, Philadelphia, 1978.
41. Vyas GN: 个人通讯.
42. Skelly J et al: Nature, 290(5801): 51-54, 1981.
43. Zuckerman AJ et al: Hepatitis Virus of Man, p213-216, Academic Press, 1979.
44. Tiollais P et al: Science, 213: 406-411, 1981.

曾接种麻疹活疫苗的儿童发生麻疹原因的探讨

辽宁省防疫站 戴德生 李春英 沈阳市和平区防疫站 杜春芬 张文媛

近年来我省麻疹发病率较应用麻疹活疫苗最初几年有回升,在某些麻疹病例中是曾接种麻疹活疫苗的儿童。为探讨其原因,我们作了调查,结果如下:

1980年于麻疹流行期间,收集曾接种麻疹但发生了麻疹的患儿的急性期血清。用2个血凝单位抗原测定血抑抗体,用2ME进行抗体反应类型分类,如果血清经2ME处理后血抑抗体滴度呈四倍下降,说明主要是IgM抗体,定为初次反应,即原发性免疫失

败,如果血抑抗体不呈四倍下降,为二次反应虽麻疹疫苗免疫成功,但因抗体消失或很低而感染发病。结果在53例病人中有26人为初次反应,占49.06%; 27人为二次反应,占50.94%。据此,我们认为曾接种麻疹而又发生麻疹的病人中,有相当一部分系属基础免疫失败,即原先的免疫没有成功。这也是当前麻疹发生的一个原因。